VAUGHAN, Ontario--(

--(

BUSINESS WIRE

商业热线

)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced an affiliate has acquired Whitecap Biosciences, LLC, which is currently developing two innovative therapies for potential use in glaucoma and geographic atrophy (GA).

)--Bausch+Lomb Corporation（NYSE/TSX:BLCO）是一家致力于帮助人们更好地视力以更好地生活的全球领先眼科健康公司，今天宣布一家附属公司收购了Whitecap Biosciences，LLC，该公司目前正在开发两种创新疗法，用于青光眼和地理萎缩（GA）的潜在用途。

The acquisition strengthens Bausch + Lomb’s expanding clinical-stage pipeline..

此次收购加强了博士伦不断扩大的临床阶段渠道。。

“

“

We’re focused on finding treatments that address unmet needs or significantly improve upon the current standard of care,” said Yehia Hashad, MD, chief medical officer and executive vice president, Research & Development, Bausch + Lomb. “

我们专注于寻找解决未满足需求或显着改善当前护理标准的治疗方法，”博士伦博士伦首席医疗官兼研发执行副总裁Yehia Hashad医学博士说。“”

Glaucoma and geographic atrophy are two areas where we believe that dramatic improvement is possible. Whitecap Biosciences’ investigational medicines show real promise when it comes to slowing vision loss and perhaps even improving vision for patients with glaucoma, which would be a long-overdue breakthrough.”.

青光眼和地理萎缩是我们认为可能取得显着改善的两个领域。Whitecap Biosciences的研究药物在减缓视力丧失甚至改善青光眼患者视力方面显示出真正的希望，这将是一个早就应该取得的突破。”。

Whitecap Biosciences was founded in 2015 to develop novel therapies for ophthalmic diseases with a focus on glaucoma, GA and other serious eye diseases. The company successfully completed Phase 2 clinical trials for WB007, a highly potent alpha-2 adrenergic agonist, in glaucoma. Additional clinical trials are planned for both glaucoma and GA..

Whitecap Biosciences成立于2015年，旨在开发针对眼科疾病的新型疗法，重点是青光眼，GA和其他严重的眼部疾病。该公司成功完成了针对青光眼的高效α-2肾上腺素能激动剂WB007的2期临床试验。计划对青光眼和GA进行其他临床试验。。

Glaucoma is a chronic, progressive neurodegenerative disease that occurs when excessive eye pressure or other causes lead to damage of the optic nerve. As one of the leading causes of preventable blindness, glaucoma affects about four million people in the United States, but if caught early, it is possible to help slow and potentially prevent vision loss..

青光眼是一种慢性进行性神经退行性疾病，当过度眼压或其他原因导致视神经损伤时会发生。青光眼是可预防失明的主要原因之一，在美国约有400万人患有青光眼，但如果及早发现，可能有助于减缓并可能预防视力丧失。。

1-3

1-3

GA, also known as advanced dry age-related macular degeneration, affects approximately one million people in the U.S.

GA，也称为晚期干性年龄相关性黄斑变性，影响美国约100万人。

4

4

“

“

Glaucoma and geographic atrophy can cause severe vision loss, with many patients experiencing progressive deterioration,” said Scott Whitcup, MD, a founder and former chief executive officer, Whitecap Biosciences. “

青光眼和地理萎缩会导致严重的视力丧失，许多患者会逐渐恶化，”Whitecap Biosciences创始人兼前首席执行官ScottWhitcup医学博士说。“”

By joining a global leader like Bausch + Lomb, we hope Whitecap’s assets will be developed into effective treatments that improve visual outcomes for patients.”

通过加入博士伦这样的全球领导者，我们希望Whitecap的资产将发展成为有效的治疗方法，从而改善患者的视力。”

About Bausch + Lomb

关于鲍施

Bausch + Lomb is dedicated to protecting and enhancing the gift of sight for millions of people around the world – from birth through every phase of life. Its comprehensive portfolio of approximately 400 products includes contact lenses, lens care products, eye care products, ophthalmic pharmaceuticals, over-the-counter products and ophthalmic surgical devices and instruments.

博士伦致力于保护和增强世界各地数百万人的视力，从出生到生命的每个阶段。其拥有约400种产品的综合产品组合，包括隐形眼镜、镜片护理产品、眼部护理产品、眼科药品、非处方产品以及眼科手术设备和仪器。

Founded in 1853, Bausch + Lomb has a significant global research and development, manufacturing, and commercial footprint with approximately 13,000 employees and a presence in nearly 100 countries. Bausch + Lomb is headquartered in Vaughan, Ontario, with corporate offices in Bridgewater, New Jersey.

博士伦公司成立于1853年，在全球拥有重要的研发、制造和商业足迹，拥有约13000名员工，业务遍及近100个国家。博士伦总部位于安大略省沃恩，公司办事处位于新泽西州布里奇沃特。

For more information, visit .

有关更多信息，请访问。

www.bausch.com

www.bausch.com

and connect with us on

并与我们联系

X

十

,

,

LinkedIn

LinkedIn

,

,

Facebook

脸书

and

和

Instagram

Instagram

.

.

About Whitecap Biosciences, LLC

关于Whitecap Biosciences，LLC

Whitecap Biosciences is a pharmaceutical company founded in 2015 and focused on novel therapies for ophthalmic diseases, including two of the leading causes of blindness in ophthalmology: glaucoma and geographic atrophy. The company is developing a compound called WB007, a highly potent alpha-2 adrenergic agonist, for an indication of vision improvement in patients with glaucoma.

Whitecap Biosciences是一家成立于2015年的制药公司，专注于眼科疾病的新型疗法，包括眼科失明的两个主要原因：青光眼和地理萎缩。该公司正在开发一种名为WB007的化合物，它是一种高效的α-2肾上腺素能激动剂，用于指示青光眼患者的视力改善。

The company is also planning a clinical program for both WB007 and WB006 for geographic atrophy..

该公司还计划为WB007和WB006的地理萎缩制定临床计划。。

Forward-looking Statements

前瞻性声明

This news release may contain forward-looking statements, which may generally be identified by the use of the words “anticipates,” “hopes,” “expects,” “intends,” “plans,” “should,” “could,” “would,” “will,” “may,” “believes,” “estimates,” “potential,” “target,” or “continue” and variations or similar expressions.

本新闻稿可能包含前瞻性陈述，这些陈述通常可以通过使用“预期”、“希望”、“预期”、“打算”、“计划”、“应该”、“可能”、“会”、“会”、“会”、“可能”、“相信”、“估计”、“潜在”、“目标”或“继续”等词语以及变体或类似表达来识别。

These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties discussed in Bausch + Lomb’s filings with the U.S.

这些声明基于当前管理层的期望和信念，并受到某些风险和不确定性的影响，这些风险和不确定性可能导致实际结果与前瞻性声明中描述的结果存在重大差异。这些风险和不确定性包括但不限于博士伦向美国提交的文件中讨论的风险和不确定性。

Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Bausch + Lomb undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this news release or to reflect actual outcomes, unless required by law..

证券交易委员会和加拿大证券管理人，这些因素通过引用纳入本文。提醒读者不要过度依赖这些前瞻性陈述。这些前瞻性声明仅在本协议签署之日有效。博士伦没有义务更新任何前瞻性声明，以反映本新闻发布日期后的事件或情况，或反映实际结果，除非法律要求。。

References

参考文献

National Eye Institute. Glaucoma and Eye Pressure. Retrieved from

国家眼科研究所。青光眼和眼压。检索自

https://www.nei.nih.gov/learn-about-eye-health/eye-conditions-and-diseases/glaucoma/glaucoma-and-eye-pressure

https://www.nei.nih.gov/learn-about-eye-health/eye-conditions-and-diseases/glaucoma/glaucoma-and-eye-pressure

. Reviewed on Nov. 12, 2024.

.于2024年11月12日审查。

John Hopkins. Glaucoma. Retrieved from

约翰·霍普金斯。青光眼。检索自

https://www.hopkinsmedicine.org/health/conditions-and-diseases/glaucoma

https://www.hopkinsmedicine.org/health/conditions-and-diseases/glaucoma

. Reviewed on Nov. 12, 2024.

.于2024年11月12日审查。

Ehrlich JR, Burke-Conte Z, Wittenborn JS, et al. Prevalence of Glaucoma Among US Adults in 2022. JAMA Ophthalmol. 2024;142(11):1046–1053. doi:10.1001/jamaophthalmol.2024.3884

Ehrlich JR，Burke Conte Z，Wittenborn JS等。2022年美国成年人青光眼患病率。JAMA眼科。2024年；142（11）：1046-1053。doi:10.1001/jamaophthalmol.2024.3884

Saundankar V, Borns M, Broderick K, et al. Annual prevalence of geographic atrophy and wet age-related macular degeneration among Medicare Advantage enrollees in a US health plan. J. of Managed Care & Specialty Pharmacy 31(1). doi.org/10.18553/jmcp.2025.31.1.88

Saundankar V，Borns M，Broderick K等。美国健康计划中Medicare Advantage参与者中地理萎缩和湿性年龄相关性黄斑变性的年度患病率。J、 管理护理和专科药房31（1）。doi.org/10.18553/jmcp.2025.31.1.88

© 2025 Bausch + Lomb.

© 2025年博士伦。